Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amryt Pharma Plc ADR (NQ: AMYT )

7.780 -0.140 (-1.77%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82,869
Open 7.880
Bid (Size) 7.760 (1)
Ask (Size) 7.860 (2)
Prev. Close 7.920
Today's Range 7.620 - 7.980
52wk Range 5.610 - 13.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc. 
Via SBWire
Recap: Amryt Pharma Q1 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-27.56%
-27.56%
1 Month
+2.91%
+2.91%
3 Month
-13.84%
-13.84%
6 Month
-32.87%
-32.87%
1 Year
-34.68%
-34.68%

More News

Read More
55 Biggest Movers From Friday
Via Benzinga
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
Via Benzinga
Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients
Via Benzinga
Recap: Amryt Pharma Q4 Earnings
Via Benzinga
Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus
Via Benzinga
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
Via Benzinga
A Preview Of Amryt Pharma's Earnings
Via Benzinga
FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder
Via Benzinga
Amryt Shares Fall After Oleogel-S10 EMA Regulatory Update
Via Benzinga
Earnings Scheduled For March 9, 2022
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Amryt's Skin Disorder Drug Application Review With FDA Extended By Three Months
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Via Benzinga
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.